A practical reference on Nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
epidemic in the 2000s is related to a number of factors. Rates of opioid use and dependency vary by age, sex, race, and socioeconomic status. With respect to race, the discrepancy in deaths is thought to be due to an interplay between physician prescribing and lack of access to healthcare and certain prescription drugs. Men are at higher risk for opioid use and dependency than women, and men also account for more opioid overdoses than women, although this gap is closing. Women are more likely to be prescribed pain relievers, be given higher doses, use them for longer durations, and become dependent upon them faster. Deaths due to opioid use also tend to skew at older ages than deaths from use of other illicit drugs. This does not reflect opioid use as a whole, which includes younger people. Overdoses from opioids are highest among people between the ages of 40 and 50, in contrast to heroin overdoses, which are highest among people between the ages of 20 and 30. 21- to 35-year-olds represent 77% of people who enter treatment for opioid use disorder, but the average age of first-time use of prescription painkillers was 21.2 years in 2013. Among the middle class, means of acquiring funds include elder financial abuse and international dealers noticing a lack of enforcement in their transaction scams throughout the Caribbean.
== Potential use == A study has shown that treatment with ondelopran reduces the amount of alcohol intake (significantly more than in the placebo group), which means it could be a good path for the treatment of alcoholism. Another test also displays more results which go in the same conclusion.
The transtheoretical model describes behavior change as a stepwise progression through a series of stages (precontemplation, contemplation, preparation, action and maintenance) through which people commonly move back and forth rather than in a single linear sequence, with relapse treated as an expected part of the process rather than a failure. In addiction treatment the model is used to gauge a person's readiness to change and to time intervention accordingly, since beginning too early may make a person defensive and resistant to change.
It was found to be teratogenic in mice and rats and fetolethal in rabbits. These effects were seen at doses lower than those used in humans. The LD50 of thiotepa via oral administration is 38 mg/kg in mice and 2,3 mg/kg in rats. For intravenous and intra-arterial injection in rats, the LD50 values are 9,5 mg/kg and 8,8 mg/kg, respectively. Women and men of childbearing potential have to use effective contraception during treatment. A pregnancy test should be performed before treatment is started. Men should not father a child during and a year after cessation of treatment. There is no data on the administration of thiotepa during pregnancy, But as in-vivo animal experiments showed teratogenic effects the use of thiotepa during pregnancy is contraindicated. It is not known whether thiotepa is excreted in human breast milk, but due to its high lipophilicity, this cannot be ruled out. Due to its pharmacological properties and potential for toxicity in newborns/infants breast feeding is contraindicated during treatment with thiotepa.
On 2 September 2025, Trump said that the US had struck a boat carrying unspecified illegal drugs, alleging it was operated by the Tren de Aragua. Trump said that the strike killed 11 "narcoterrorists". On 28 November, it was revealed that two men who survived the initial strike were killed in subsequent strikes. A second strike occurred on 15 September, killing three. The US government did not provide evidence that those killed in either strike were narco-trafficking. In a third strike on 19 September that killed three, the Dominican Republic later stated it had cooperated with the US Navy in a first-ever joint operation to locate the boat and salvage 377 packages of cocaine, weighing 1,000 kilograms (2,200 lb). On 3 October, a strike on a vessel near the coast of Venezuela killed four; anonymous US officials later declared that there were Colombians on at least one of the boats. Trump stated on 14 October that six more were killed in a strike near the coast of Venezuela. Reuters reported that another previously unannounced strike on 16 October had killed two and included two survivors who were being held on a Navy ship. By 19 October, both were repatriated to their respective countries of origin, Colombia and Ecuador. On 17 October, three were killed in a strike on an alleged drug vessel operated by the National Liberation Army (ELN) of Colombia. The ELN denied involvement in any drug boat trafficking. The first strike at night, on 24 October against an alleged drug vessel operated by Tren de Aragua in the Caribbean, killed six.
Sources: en.wikipedia.org
The editing involves cytidine deaminase that deaminates a cytidine base into a uridine base. An example of C-to-U editing is with the apolipoprotein B gene in humans. Apo B100 is expressed in the liver and apo B48 is expressed in the intestines. In the intestines, the mRNA has a CAA sequence edited to be UAA, a stop codon, thus producing the shorter B48 form. C-to-U editing often occurs in the mitochondrial RNA of flowering plants. Different plants have different degrees of C-to-U editing; for example, eight editing events occur in mitochondria of the moss Funaria hygrometrica, whereas over 1,700 editing events occur in the lycophytes Isoetes engelmanii. C-to-U editing is performed by members of the pentatricopeptide repeat (PPR) protein family. Angiosperms have large PPR families, acting as trans -factors for cis -elements lacking a consensus sequence; Arabidopsis has around 450 members in its PPR family. There have been a number of discoveries of PPR proteins in both plastids and mitochondria.
On June 30, 2009, the song "A Looking in View" was made available for purchase via iTunes and Amazon, and for a limited time it was available as a free download through the official Alice in Chains website in early July. Although it was not the album's first radio single, Rock stations across the U.S. started playing the song. The music video for "A Looking in View" debuted via the band's official website on July 7, 2009. The song was nominated for a Grammy Award for Best Hard Rock Performance. "Check My Brain" was released to radio stations as the first official single from the album on August 14, 2009, and was made available for purchase on August 17, 2009. The music video for "Check My Brain" premiered on September 14, 2009. The song was also nominated for a Grammy Award for Best Hard Rock Performance. To promote the album, the band released an EPK featuring all four of the members being interviewed while the Kiss makeup is being applied on them. An app for iPhone was released on October 27, 2009, featuring songs, music videos, news, photos and networking.
==== Spray-drying ==== As this method is traditionally used for small particles, it is used to produce tempeh powder for products such as soups, breads, tortillas, etc. However, this method can be expensive due to the bulky nature of the equipment.
The Australian Wagyu Association is the largest breed association outside Japan. Both fullblood and Wagyu-cross cattle are farmed in Australia for domestic and overseas markets, including China, Denmark, France, Germany, Hong Kong, Indonesia, Singapore, Taiwan, the United Kingdom and the United States. Australian Wagyu cattle are grain fed for the last 300–500 days of production. Wagyu bred in Western Australia's Margaret River region often have red wine added to their feed as well.
Lamina-associated polypeptide 2 (LAP2), isoforms beta/gamma is a protein that in humans is encoded by the TMPO gene. LAP2 is an inner nuclear membrane (INM) protein. Thymopoietin is a protein involved in the induction of CD90 in the thymus. The thymopoetin (TMPO) gene encodes three alternatively spliced mRNAs encoding proteins of 75 kDa (alpha), 51 kDa (beta) and 39 kDa (gamma) which are ubiquitously expressed in all cells. The human TMPO gene maps to chromosome band 12q22 and consists of eight exons. TMPO alpha is present diffusely expressed with the cell nucleus while TMPO beta and gamma are localized to the nuclear membrane. TMPO beta is a human homolog of the murine protein LAP2. LAP2 plays a role in the regulation of nuclear architecture by binding lamin B1 and chromosomes. This interaction is regulated by phosphorylation during mitosis. Given the nuclear localization of the three TMPO isoforms, it is unlikely that these proteins play any role in CD90 induction.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.